SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Clinical trial NCT06080776 · RECRUITING

Trial details

NCT number: NCT06080776
Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2023-05-11
Primary completion: 2028-02-01
Enrollment: 242

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.